Company Edwards Lifesciences Corporation
Equities
EW
US28176E1082
Advanced Medical Equipment & Technology
Real-time Estimate
Other stock markets
|
|
5-day change | 1st Jan Change | |
67.38 USD | -3.04% | -0.53% | -9.73% |
Business Summary
- hemodynamic monitoring systems (65.4%);
- heart valves and surgery products (18.7%);
- other (15.9%): balloon catheters, artificial implants, etc.
Net sales are distributed geographically as follows: the United States (58.2%), Europe (21.8%), Japan (8.8%) and other (11.2%).
Number of employees : 17,300
Sales per Business
USD in Million | 2021 | Weight | 2022 | Weight | Delta |
---|---|---|---|---|---|
Transcatheter Aortic Valve Replacement
65.4
%
| 3,423 | 65.4 % | 3,518 | 65.4 % | +2.80% |
Surgical Structural Heart
16.6
%
| 889 | 17.0 % | 893 | 16.6 % | +0.45% |
Critical Care
15.9
%
| 835 | 16.0 % | 855 | 15.9 % | +2.41% |
Transcatheter Mitral and Tricuspid Therapies
2.2
%
| 86 | 1.6 % | 116 | 2.2 % | +35.00% |
Sales per region
USD in Million | 2021 | Weight | 2022 | Weight | Delta |
---|---|---|---|---|---|
United States
58.2
%
| 2,963 | 56.6 % | 3,133 | 58.2 % | +5.72% |
Europe
21.8
%
| 1,190 | 22.7 % | 1,175 | 21.8 % | -1.30% |
Rest of World
11.2
%
| 550 | 10.5 % | 601 | 11.2 % | +9.31% |
Japan
8.8
%
| 529 | 10.1 % | 474 | 8.8 % | -10.46% |
Managers
Managers | Title | Age | Since |
---|---|---|---|
Chief Executive Officer | 56 | 2014 | |
Scott Ullem
DFI | Director of Finance/CFO | 56 | 2013 |
Chairman | 70 | 1999 | |
Todd Brinton
CTO | Chief Tech/Sci/R&D Officer | - | 2019 |
Investor Relations Contact | - | - | |
Linda J. Park
LAW | General Counsel | 45 | - |
Corporate Officer/Principal | 64 | 2017 | |
Tammy Perry
PRN | Corporate Officer/Principal | - | 2011 |
Donald E. Bobo
PRN | Corporate Officer/Principal | 61 | 1994 |
Catherine Szyman
PRN | Corporate Officer/Principal | 56 | 2014 |
Members of the board
Members of the board | Title | Age | Since |
---|---|---|---|
Leslie Heisz
BRD | Director/Board Member | 62 | 2016 |
Director/Board Member | 66 | 2014 | |
Steven Loranger
BRD | Director/Board Member | 71 | 2016 |
Chairman | 70 | 1999 | |
Paul LaViolette
BRD | Director/Board Member | 65 | 2020 |
Kieran Gallahue
BRD | Director/Board Member | 59 | 2015 |
Martha H. Marsh
BRD | Director/Board Member | 74 | 2015 |
Ramona Sequeira
BRD | Director/Board Member | 57 | 2020 |
Chief Executive Officer | 56 | 2014 |
Share class
Vote | Quantity | Free-Float | Company-owned shares | Total Float | |
---|---|---|---|---|---|
Stock A | 1 | 649,900,000 | 601,270,967 ( 92.52 %) | 43,400,000 ( 6.678 %) | 92.52 % |
Company contact information

Group companies
Name | Category and Sector |
---|---|
Edwards Lifesciences World Trade Corp.
|
Health Technology - Medical Specialties
|
Edwards Lifesciences Technology SARL
|
-
|
Edwards Lifesciences (India) Pvt Ltd.
|
Health Technology - Medical Specialties
|
Sector
Sales per Business
Sales per region
Trading Rating :
Investor Rating :
ESG Refinitiv :
B+
Sell
Buy

Mean consensus
OUTPERFORM
Number of Analysts
30
Last Close Price
69.49USD
Average target price
79.36USD
Spread / Average Target
+14.20%
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-9.73% | 42 146 M $ | |
-10.05% | 191 B $ | |
-17.33% | 163 B $ | |
+16.66% | 109 B $ | |
+18.39% | 80 310 M $ | |
+11.71% | 63 346 M $ | |
-10.43% | 47 620 M $ | |
-13.40% | 37 658 M $ | |
+14.87% | 30 979 M $ | |
-21.80% | 24 121 M $ |
- Stock
- Equities
- Stock Edwards Lifesciences Corporation - Nyse
- Company Edwards Lifesciences Corporation